Amedica And K2M Partner To Expand Distribution Of Silicon Nitride Interbody Spinal Fusion Devices In Europe

SALT LAKE CITY and LEESBURG, Va., Oct. 24, 2013 /PRNewswire/ -- Amedica Corporation, a biomaterial company, announced today that it has entered into a distribution agreement with K2M that will provide surgeons and hospitals in Europe with access to Amedica's Silicon Nitride interbody spinal fusion devices. K2M is the largest privately-held spinal device company in the world.

Earlier this year, Amedica and K2M conducted a successful pilot program in select markets in Europe where surgeons were provided the opportunity to integrate Silicon Nitride interbody devices into their offerings for patients suffering from a variety of disorders requiring spinal fusion. This pilot program demonstrated a need in these strategic markets for spinal fusion devices devised from a different biomaterial.

"K2M is committed to providing the best and most innovative technologies to meet the needs of patients around the world suffering from spinal disorders and we believe our relationship with Amedica will help us further this goal," said Eric Major, K2M's President and Chief Executive Officer. "We are thrilled to make Amedica's Silicon Nitride interbody spinal fusion devices part of our comprehensive international product portfolio."

"K2M has an outstanding sales and marketing team that has created a global reputation for providing leading edge technology to their customers. Our Silicon Nitride interbody product line will be integrated into K2M's current portfolio of interbody spinal fusion devices," said Eric K. Olson, President and Chief Executive Officer, Amedica. "We believe it is evident that there is a need in Europe for interbody fusion devices that exceed the capabilities of existing PEEK and Titanium-based devices. With this distribution channel in place, we believe Silicon Nitride interbody spinal fusion devices will increasingly be the solution that surgeons rely on to deliver optimal patient outcomes in spinal fusion procedures."

About Amedica Corporation:
Amedica is a commercial biomaterial company focused on using its Silicon Nitride technology platform to develop, manufacture and sell a broad range of medical devices.  Amedica markets spinal fusion products and is developing products for use in total hip and knee joint replacements.  Amedica is a privately owned company founded in 1996. The company operates an ISO 13485 certified manufacturing facility, and, its spine products are FDA cleared, CE marked, and are currently marketed in the US and select markets in Europe and South America. Amedica is based in Salt Lake City, Utah.

About K2M:
K2M, Inc. is the largest privately held spinal device company in the world focused on the research, development, and commercialization of innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures. The company is recognized as a global leader in providing unique technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patients. K2M's product development pipeline includes: spinal stabilization systems, minimally invasive systems, biologics, and other advancing technologies, such as motion preservation, annular repair, and nucleus replacement. Additional information is available online at www.K2M.com.

Media Contacts
Stacey Holifield / Stacy Nartker on behalf of Amedica Corporation
Schwartz MSL
(781) 684-0770
[email protected]

Media Contact
Zeno Group on behalf of K2M, Inc.
Marcie Kohenak
(202) 965-7811
[email protected]

SOURCE Amedica Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED